The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT
Open accessThe DOI matches its Crossref record; 92 of the 92 references it cites were found in a registry or an index.
Abstract
Perhaps the best-studied mucosal adjuvants are the bacterially derived ADP-ribosylating enterotoxins. This adjuvant family includes heat-labile enterotoxin of Escherichia coli (LT), cholera toxin (CT), and mutants or subunits of LT and CT.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Interestingly, a double-mutant labile toxin (dmLT) derived from Escherichia coli is a potent adjuvant that can enhance immune responses to IPV [113,114,115,116].”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [114]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Doreau, A., Belot, A., Bastid, J., Riche, B., Trescol-Biemont, M.-C., Ranchin, B., Fabien, N., Cochat, P., Pouteil-Noble, C., Trolliet, P., et al. (2009) · Nature Immunology · doi:10.1038/ni.1741 · Cited by 452
RetractedTrained immunity: A program of innate immune memory in health and– disease
Netea, M. G., Joosten, L. A. B., Latz, E., Mills, K. H. G., Natoli, G., Stunnenberg, H. G., O’Neill, L. A. J., & Xavier, R. J. (2016) · Science · doi:10.1126/science.aaf1098 · Cited by 2,768
Use of the Inactivated Intranasal Influenza Vaccine and the Risk of Bell's Palsy in Switzerland
Mutsch, M., Zhou, W., Rhodes, P., Bopp, M., Chen, R. T., Linder, T., Spyr, C., & Steffen, R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030595 · Cited by 916
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development
Levine, M. M., Kaper, J. B., Black, R. E., & Clements, M. L. (1983) · Microbiological Reviews · doi:10.1128/mmbr.47.4.510-550.1983 · Cited by 636
Intestinal ion transport and the pathophysiology of diarrhea
Field, M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18326 · Cited by 572
Proinflammatory T helper type 17 cells are effective B-cell helpers
Mitsdoerffer, M., Lee, Y., Jäger, A., Kim, H.-J., Korn, T., Kolls, J. K., Cantor, H., Bettelli, E., & Kuchroo, V. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009234107 · Cited by 534
Interleukin 17 is a chief orchestrator of immunity
Veldhoen, M. (2017) · Nature Immunology · doi:10.1038/ni.3742 · Cited by 475
Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin.
Elson, C. O., & Ealding, W. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.6.2736 · Cited by 444
Dickinson, B. L., & Clements, J. D. (1995) · Infection and Immunity · doi:10.1128/iai.63.5.1617-1623.1995 · Cited by 350
Self-citationClements, J. D., & Finkelstein, R. A. (1979) · Infection and Immunity · doi:10.1128/iai.24.3.760-769.1979 · Cited by 330
Self-citation
Research works printed but not linked: 4
- Oplinger ML, Baqar S, Trofa AF, Clements JD, Gibbs P, Pazzaglia G, Bourgeois AL, Scott DA. 1997. Safety and immunogenicity in volunteers of a new candidate oral mucosal adjuvant, LT(R192G), p 193. Abstr 37th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
- 10.1128/mr.47.4.510-550.1983 · doi:10.1128/mr.47.4.510-550.1983 · Paper page
- Tribble DR, Baqar S, Thompson SA. 2008. Development of a human vaccine, p 429–444. In Nachamkin I, Szymanski CM, Blaser MJ (ed), Campylobacter, 3rd ed. ASM Press, Washington, DC.
- 10.1002/1521-4141(2000)30:8<2394::aid-immu2394>3.0.co;2-y · DOI · Paper page
Cited by
Mucosal vaccines — fortifying the frontiers
Lavelle, E. C., & Ward, R. W. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00583-2 · Cited by 752
Recombinant protein vaccines, a proven approach against coronavirus pandemics
Pollet, J., Chen, W.-H., & Strych, U. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.001 · Cited by 277
Pokharel, P., Dhakal, S., & Dozois, C. M. (2023) · Microorganisms · doi:10.3390/microorganisms11020344 · Cited by 207
New-age vaccine adjuvants, their development, and future perspective
Verma, S. K., Mahajan, P., Singh, N. K., Gupta, A., Aggarwal, R., Rappuoli, R., & Johri, A. K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1043109 · Cited by 190
Chitosan-Based Nanomaterial as Immune Adjuvant and Delivery Carrier for Vaccines
Gong, X., Gao, Y., Shu, J., Zhang, C., & Zhao, K. (2022) · Vaccines · doi:10.3390/vaccines10111906 · Cited by 155
Enterotoxigenic Escherichia coli Infections
Fleckenstein, J. M., & Kuhlmann, F. M. (2019) · Current Infectious Disease Reports · doi:10.1007/s11908-019-0665-x · Cited by 130
Developments in Vaccine Adjuvants
Firdaus, F. Z., Skwarczyński, M., & Tóth, I. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1892-9_8 · Cited by 122
Qadri, F., Akhtar, M., Bhuiyan, T. R., Chowdhury, M. I., Ahmed, T., Rafique, T. A., Khan, A., Rahman, S. I. A., Khanam, F., Lundgren, A., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30571-7 · Cited by 118
Understanding Pseudomonas aeruginosa–Host Interactions: The Ongoing Quest for an Efficacious Vaccine
Sainz-Mejías, M., Jurado‐Martín, I., & McClean, S. (2020) · Cells · doi:10.3390/cells9122617 · Cited by 104
Production and Function of Immunoglobulin A
Hand, T. W., & Reboldi, A. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-102119-074236 · Cited by 97
Duan, Q., Xia, P., Nandre, R. M., Zhang, W., & Zhu, G. (2019) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2019.00292 · Cited by 93
Vaccine-driven lung TRM cells provide immunity against Klebsiella via fibroblast IL-17R signaling
Iwanaga, N., Chen, K., Yang, H., Lu, S., Hoffmann, J. P., Wanek, A. G., McCombs, J. E., Song, K., Rangel‐Moreno, J., Norton, E. B., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf1198 · Cited by 92
Self-citationAdvances in Oral Subunit Vaccine Design
der Weken, H. V., Cox, E., & Devriendt, B. (2020) · Vaccines · doi:10.3390/vaccines9010001 · Cited by 88
Mucosal immunity and vaccination strategies: current insights and future perspectives
Zhang, Z., Hong, W., Zhang, Y., Li, X., Que, H., & Wei, X. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00301-7 · Cited by 85
Bhattacharjee, A., Burr, A. B. P., Overacre-Delgoffe, A. E., Tometich, J. T., Yang, D., Huckestein, B. R., Linehan, J. L., Spencer, S. P., Hall, J. A., Harrison, O. J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.07.005 · Cited by 80
Self-citationJones, A., Shen, X., Walter, K. A., LaBranche, C. C., Wyatt, L. S., Tomaras, G. D., Montefiori, D. C., Moss, B., Barouch, D. H., Clements, J. D., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08739-4 · Cited by 78
Self-citationMucosal plasma cells are required to protect the upper airway and brain from infection
Wellford, S. A., Moseman, A. P., Dao, K., Wright, K., Chen, A. P., Plevin, J. E., Liao, T.-C., Mehta, N. U., & Moseman, E. A. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.017 · Cited by 78
Coffey, J. W., Gaiha, G. D., & Traverso, G. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030320-092348 · Cited by 77
Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens
Dotiwala, F., & Upadhyay, A. (2023) · Vaccines · doi:10.3390/vaccines11101585 · Cited by 76
Mucosal vaccination: onward and upward
Tsai, C. J., Loh, J. M. S., Fujihashi, K., & Kiyono, H. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2268724 · Cited by 73
Mucosal immunity to poliovirus
Connor, R. I., Brickley, E. B., Wieland‐Alter, W., Ackerman, M. E., Weiner, J. A., Modlin, J. F., Bandyopadhyay, A. S., & Wright, P. F. (2021) · Mucosal Immunology · doi:10.1038/s41385-021-00428-0 · Cited by 72
Review: Current trends, challenges, and success stories in adjuvant research
Singleton, K. L., Joffe, A. R., & Leitner, W. W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1105655 · Cited by 61
Recombinant lactic acid bacteria as promising vectors for mucosal vaccination
Qiao, N., Du, G., Zhong, X., & Sun, X. (2021) · Exploration · doi:10.1002/exp.20210026 · Cited by 60
Recent progress in application of nanovaccines for enhancing mucosal immune responses
Du, G., Qin, M., & Sun, X. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.010 · Cited by 58
Olfactory immunology: the missing piece in airway and CNS defence
Wellford, S. A., & Moseman, E. A. (2023) · Nature reviews. Immunology · doi:10.1038/s41577-023-00972-9 · Cited by 56
Li, J., Wu, G., Huang, Z., Hu, J., Tie, X., Wu, H., Wang, Z., & Chen, K. (2025) · npj Vaccines · doi:10.1038/s41541-025-01280-0 · Cited by 60
Controlled Human Infection Models To Accelerate Vaccine Development
Choy, R. K. M., Bourgeois, A. L., Ockenhouse, C. F., Walker, R. I., Sheets, R., & Flores, J. (2022) · Clinical Microbiology Reviews · doi:10.1128/cmr.00008-21 · Cited by 59
Development of Nasal Vaccines and the Associated Challenges
Nian, X., Zhang, J., Huang, S., Duan, K., Li, X., & Yang, X. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14101983 · Cited by 58
Sublingual vaccination and delivery systems
Paris, A.-L., Colomb, E., Verrier, B., Anjuère, F., & Monge, C. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.03.017 · Cited by 51
Immunomodulation therapy offers new molecular strategies to treat UTI
Butler, D. S. C., Ambite, I., Wan, M. L. Y., Tran, T. H., Wullt, B., & Svanborg, C. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00602-4 · Cited by 55
Development of mucosal vaccine delivery: an overview on the mucosal vaccines and their adjuvants
Anggraeni, R., Ana, I. D., & Wihadmadyatami, H. (2022) · Clinical and Experimental Vaccine Research · doi:10.7774/cevr.2022.11.3.235 · Cited by 49
Optimization of an Experimental Vaccine To Prevent Escherichia coli Urinary Tract Infection
Forsyth, V. S., Himpsl, S. D., Smith, S. N., Sarkissian, C. A., Mike, L. A., Stocki, J. A., Sintsova, A., Alteri, C. J., & Mobley, H. L. T. (2020) · mBio · doi:10.1128/mbio.00555-20 · Cited by 47
Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity
Li, Z., Zhao, Y., Li, Y., & Chen, X. (2021) · Vaccines · doi:10.3390/vaccines9020075 · Cited by 45
Stone, A. E., Scheuermann, S. E., Haile, C. N., Cuny, G. D., Velasquez, M. L., Linhuber, J., Duddupudi, A. L., Vigliaturo, J. R., Pravetoni, M., Kosten, T. A., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00329-0 · Cited by 47
Self-citationVaccines for Protecting Infants from Bacterial Causes of Diarrheal Disease
Walker, R. I., Kaminski, R. W., Porter, C. K., Choy, R. K. M., White, J. A., Fleckenstein, J. M., Cassels, F., & Bourgeois, L. (2021) · Microorganisms · doi:10.3390/microorganisms9071382 · Cited by 48
Novotny, L. A., Goodman, S. D., & Bakaletz, L. O. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102867 · Cited by 45
Confronting Challenges to Enterotoxigenic Escherichia coli Vaccine Development
Fleckenstein, J. M. (2021) · Frontiers in Tropical Diseases · doi:10.3389/fitd.2021.709907 · Cited by 43
Kantele, A., Riekkinen, M., Jokiranta, T. S., Pakkanen, S. H., Pietilä, J.-P., Patjas, A., Eriksson, M., Khawaja, T., Klemets, P., Marttinen, K., et al. (2023) · Journal of Travel Medicine · doi:10.1093/jtm/taad045 · Cited by 40
Novotny, L. A., Goodman, S. D., & Bakaletz, L. O. (2019) · npj Vaccines · doi:10.1038/s41541-019-0137-1 · Cited by 41
Identification of Conserved Candidate Vaccine Antigens in the Surface Proteome of Giardia lamblia
Davids, B. J., Liu, C. M., Hanson, E. M., Le, C., Ang, J., Hanevik, K., Fischer, M., Radunovic, M., Langeland, N., Ferella, M., et al. (2019) · Infection and Immunity · doi:10.1128/iai.00219-19 · Cited by 38
Valli, E., Harriett, A. J., Nowakowska, M. K., Baudier, R. L., Provosty, W. B., McSween, Z., Lawson, L. B., Nakanishi, Y., & Norton, E. B. (2019) · Scientific Reports · doi:10.1038/s41598-019-51356-w · Cited by 39
Self-citationCEACAMs serve as toxin-stimulated receptors for enterotoxigenic Escherichia coli
Sheikh, A., Tumala, B., Vickers, T. J., Alvarado, D. M., Ciorba, M. A., Bhuiyan, T. R., Qadri, F., Singer, B. B., & Fleckenstein, J. M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012480117 · Cited by 40
Vaccination Strategies Based on Bacterial Self-Assembling Proteins as Antigen Delivery Nanoscaffolds
Lamontagne, F., Khatri, V., St‐Louis, P., Bourgault, S., & Archambault, D. (2022) · Vaccines · doi:10.3390/vaccines10111920 · Cited by 39
Recent advances in enterotoxin vaccine adjuvants
Crothers, J. W., & Norton, E. B. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102398 · Cited by 35
Self-citationThe Fight against Poliovirus Is Not Over
Mbani, C. J., Nekoua, M. P., Moukassa, D., & Hober, D. (2023) · Microorganisms · doi:10.3390/microorganisms11051323 · Cited by 34
Technological Approaches for Improving Vaccination Compliance and Coverage
Lemoine, C., Thakur, A., Krajišnik, D. R., Guyon, R., Longet, S., Razim, A., Górska, S., Pantelić, I., Milić, J., Nikolić, I., et al. (2020) · Vaccines · doi:10.3390/vaccines8020304 · Cited by 34
Das, S., Howlader, D. R., Zheng, Q., Ratnakaram, S. S. K., Whittier, S. K., Lu, T., Keith, J. D., Picking, W. D., Birket, S. E., & Picking, W. L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583008 · Cited by 33
Liang, H., Poncet, D., Seydoux, E., Rintala, N. D., Maciel, M., Ruiz, S., & Orr, M. T. (2019) · npj Vaccines · doi:10.1038/s41541-019-0116-6 · Cited by 32
Haile, C. N., Baker, M. D., Sanchez, S. A., Arteaga, C. A. L., Duddupudi, A. L., Cuny, G. D., Norton, E. B., Kosten, T. R., & Kosten, T. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14112290 · Cited by 30
Self-citationDeclercq, J., Gerlo, S., Nevel, S. V., Ruyck, N. D., Holtappels, G., Delesie, L. M., Tobback, E., Lammens, I., Gerebtsov, N., Sedeyn, K., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adn2364 · Cited by 31
Sahu, R., Dixit, S., Verma, R., Duncan, S. A., Coats, M. T., Giambartolomei, G. H., Singh, S. R., & Dennis, V. A. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102257 · Cited by 28
Maciel, M., Bauer, D. L., Baudier, R. L., Bitoun, J. P., Clements, J. D., Poole, S., Smith, M. A., Kaminski, R. W., Savarino, S. J., & Norton, E. B. (2019) · Infection and Immunity · doi:10.1128/iai.00460-19 · Cited by 28
Self-citationAkhtar, M., Nizam, N. N., Basher, S. R., Hossain, L., Akter, S., Bhuiyan, T. R., Qadri, F., & Lundgren, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654872 · Cited by 27
Svennerholm, A., Lundgren, A., Leach, S., Akhtar, M., & Qadri, F. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab475 · Cited by 27
Adjuvants: Engineering Protective Immune Responses in Human and Veterinary Vaccines
Akache, B., Stark, F. C., Agbayani, G., Renner, T. M., & McCluskie, M. J. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1892-9_9 · Cited by 32
Inactivated Poliovirus Vaccine: Recent Developments and the Tortuous Path to Global Acceptance
Sutter, R. W., Eisenhawer, M., Molodecky, N. A., Verma, H., & Okayasu, H. (2024) · Pathogens · doi:10.3390/pathogens13030224 · Cited by 30
Kuhlmann, F., Laine, R., Afrin, S., Nakajima, R., Akhtar, M., Vickers, T. J., Parker, K. C., Nizam, N. N., Grigura, V., Goss, C. W., et al. (2021) · Infection and Immunity · doi:10.1128/iai.00041-21 · Cited by 27
Riddle, M. S., Maciel, M., Porter, C. K., Poole, S., Gutiérrez, R. L., Gormley, R., Laird, R. M., Sebeny, P. J., Dori, K. E., Greenleaf, M. E., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.09.025 · Cited by 26
Doss-Gollin, S., Thomas, S., Brook, B., Abedi, K., Lebas, C., Auderset, F., Rodriguez, Y. L., Sánchez‐Schmitz, G., Dowling, D. J., Levy, O., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00759-y · Cited by 26
Sakkestad, S. T., Steinsland, H., Skrede, S., Lillebø, K., Skutlaberg, D. H., Guttormsen, A. B., Zavialov, A. V., Paavilainen, S., Søyland, H., Sævik, M., et al. (2019) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0007823 · Cited by 27
Zhong, Y., Chen, J., Liu, Y., Zhang, Y., Tang, C., Wang, X., Wang, P., Chen, W., Wei, B., & Liu, M. (2020) · Microbial Pathogenesis · doi:10.1016/j.micpath.2020.104229 · Cited by 26
Svennerholm, A., Qadri, F., Lundgren, A., Kaim, J., Bhuiyan, T. R., Akhtar, M., Maier, N., Bourgeois, A. L., & Walker, R. I. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.10.056 · Cited by 25
Recent development of oral vaccines (Review)
Liu, Y., Lam, D. M., Luan, M., Zheng, W., & Ai, H. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12511 · Cited by 27
Riccomi, A., Piccaro, G., Christensen, D., Palma, C., Andersen, P. L., & Vendetti, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00934 · Cited by 24
Final frontiers of the polio eradication endgame
Bandyopadhyay, A. S., & Macklin, G. (2020) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000667 · Cited by 24
Vaccines as Immunotherapies for Substance Use Disorders
Kosten, T. R. (2024) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230828 · Cited by 22
Peletta, A., Lemoine, C., Courant, T., Collin, N., & Borchard, G. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106699 · Cited by 22
So, K.-K., Le, N. M. T., Nguyen, N.-L., & Kim, D. (2023) · Microbial Cell Factories · doi:10.1186/s12934-023-02065-7 · Cited by 20
Sukwa, N., Mubanga, C., Hatyoka, L. M., Chilyabanyama, O. N., Chibuye, M., Mundia, S., Munyinda, M., Kamuti, E., Siyambango, M., Badiozzaman, S., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.09.052 · Cited by 20
Developments in oral enterotoxigenic Escherichia coli vaccines
Svennerholm, A., & Lundgren, A. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102372 · Cited by 19
Ma, J., Hermans, L., Dierick, M., der Weken, H. V., Cox, E., & Devriendt, B. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2399215 · Cited by 19
Kadry, N. A., Porsch, E. A., Shen, H., & Geme, J. W. S. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019923118 · Cited by 19
Toprani, V. M., Sahni, N., Hickey, J. M., Robertson, G. A., Middaugh, C. R., Joshi, S. B., & Volkin, D. B. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.101 · Cited by 19
Crothers, J. W., Ross Colgate, E., Cowan, K. J., Dickson, D. M., Walsh, M., Carmolli, M., Wright, P. F., Norton, E. B., & Kirkpatrick, B. D. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.056 · Cited by 18
Self-citationRecent Advances in the Development of Adenovirus-Vectored Vaccines for Parasitic Infections
Koger-Pease, C., Perera, D. J., & Ndao, M. (2023) · Pharmaceuticals · doi:10.3390/ph16030334 · Cited by 20
Valli, E., Baudier, R. L., Harriett, A. J., & Norton, E. B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0227047 · Cited by 18
Self-citationBroad protective vaccination against systemic Escherichia coli with autotransporter antigens
Xing, Y., Clark, J. R., Chang, J. D., Chirman, D. M., Green, S. I., Zulk, J. J., Jelinski, J., Patras, K. A., & Maresso, A. W. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011082 · Cited by 18
Maciel, M., Smith, M. A., Poole, S., Laird, R. M., Rollenhagen, J. E., Kaminski, R. W., Wenzel, H., Bourgeois, A. L., & Savarino, S. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224073 · Cited by 18
The development of a human Brucella mucosal vaccine: What should be considered?
Tian, T., Zhu, Y., Shi, J., Shang, K., Yin, Z., Shi, H., He, Y., Ding, J., & Zhang, F. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122986 · Cited by 18
Development and function of tissue-resident memory B cells
Chen, C., & Laidlaw, B. J. (2022) · Advances in immunology · doi:10.1016/bs.ai.2022.08.001 · Cited by 18
Conserved metabolic enzymes as vaccine antigens for giardiasis
Ihara, S., Miyamoto, Y., Le, C. H. Y., Tran, V. N., Hanson, E. M., Fischer, M., Hanevik, K., & Eckmann, L. (2022) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0010323 · Cited by 16
Shigella virulence protein VirG is a broadly protective antigen and vaccine candidate
Desalegn, G., Tamilselvi, C. S., Lemme‐Dumit, J. M., Heine, S. J., Dunn, D., Ndungo, E., Kapoor, N., Oaks, E. V., Fairman, J., & Pasetti, M. F. (2024) · npj Vaccines · doi:10.1038/s41541-023-00797-6 · Cited by 15
Metabolic fitness of IgA+ plasma cells in the gut requires DOCK8
Zhang, B., Chen, S., Yin, X., McBride, C. D., Gertie, J. A., Yurieva, M., Bielecka, A. A., Hoffmann, B. R., Hinson, J. T., Grassmann, J. D. S., et al. (2023) · Mucosal Immunology · doi:10.1016/j.mucimm.2023.12.001 · Cited by 15
Self-citationMonge, C., Ayad, C., Paris, A.-L., Rovera, R., Colomb, E., & Verrier, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113440 · Cited by 15
Maltseva, M., Galipeau, Y., Renner, T. M., Deschatelets, L., Durocher, Y., Akache, B., & Langlois, M. (2022) · Vaccines · doi:10.3390/vaccines11010030 · Cited by 16
Bailey, M. T., Lauber, C. L., Novotny, L. A., Goodman, S. D., & Bakaletz, L. O. (2020) · mSphere · doi:10.1128/msphere.00296-20 · Cited by 14
Poncet, D., Hessler, C., Liang, H., Gautheron, S., Sergent, M., Rintala, N. D., Seydoux, E., Huang, P.-W. D., Argilla, D., Ruiz, S., et al. (2020) · npj Vaccines · doi:10.1038/s41541-020-00228-w · Cited by 14
Yan, Y., Hu, K., Fu, M., Deng, X., Luo, S., Tong, L., Guan, X., He, S., Li, C., Jin, W., et al. (2021) · mSphere · doi:10.1128/msphere.00058-21 · Cited by 14
Immunomodulation as a Novel Strategy for Prevention and Treatment of Bordetella spp. Infections
Gestal, M. C., Johnson, H. M., & Harvill, E. T. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02869 · Cited by 14
Akhtar, M., Basher, S. R., Nizam, N. N., Hossain, L., Bhuiyan, T. R., Qadri, F., & Lundgren, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1220130 · Cited by 13
Bauer, D. L., Bachnak, L., Limbert, V. M., Horowitz, R. M., Baudier, R. L., D’Souza, S. J., Immethun, V. E., Kurtz, J. R., Grant, S. B., & McLachlan, J. B. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200221 · Cited by 13
Recent strategies driving oral biologic administration
Alotaibi, B. S., Buabeid, M. A., Ibrahim, N. A., Kharaba, Z. J., Ijaz, M., & Murtaza, G. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1990044 · Cited by 13
Westcott, M. M., Blevins, M. W., Wierzba, T. F., Morse, A. E., White, K. R., Sanders, L. A., & Sanders, J. W. (2023) · Microorganisms · doi:10.3390/microorganisms11082040 · Cited by 12
Novotny, L. A., & Bakaletz, L. O. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.01.052 · Cited by 12
Ntakiyisumba, E., Lee, S., & Won, G. (2022) · Animals · doi:10.3390/ani12162136 · Cited by 13
Oral inactivated whole cell vaccine for mucosal immunization: ETVAX case study
Walker, R. I., & Bourgeois, A. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1125102 · Cited by 12
Impact of the TLR4 agonist BECC438 on a novel vaccine formulation against Shigella spp.
Lu, T., Das, S., Howlader, D. R., Jain, A., Hu, G., Dietz, Z. K., Zheng, Q., Ratnakaram, S. S. K., Whittier, S. K., Varisco, D. J., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1194912 · Cited by 12
Motyka, N. I., Stewart, S. R., Porretta, C. P., Hollifield, I. E., Bauer, D. L., & Bitoun, J. P. (2022) · Infection and Immunity · doi:10.1128/iai.00637-21 · Cited by 14
Mubanga, C., Simuyandi, M., Mwape, K., Chibesa, K., Chisenga, C. C., Chilyabanyama, O. N., Randall, A. Z., Liang, X., Glashoff, R. H., & Chilengi, R. (2023) · Vaccines · doi:10.3390/vaccines11050939 · Cited by 12
Estupiñan, J. L. M., Pind, A. A. A., Pajoohian, P. F., Jónsdóttir, I., & Bjarnarson, S. P. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1078904 · Cited by 11
Metadata
- Authors
- Clements, J. D., & Norton, E. B.
- Affiliations
- Tulane University (US)
- Corresponding author
- Norton, Elizabeth B.
- Venue
- mSphere
- Publisher
- American Society for Microbiology
- Published
- 2018-08-29
- Volume
- 3
- Issue
- 4
- ISSN
- 2379-5042 (ISSN-L)
- PMC
- PMC6060342
- OpenAlex
- W2883931539
- Cited by
- 177
- References
- 92
- Citations by year
- 2026: 16 · 2025: 14 · 2024: 14 · 2023: 40 · 2022: 21 · 2021: 29 · 2020: 27 · 2019: 15
- FWCI
- 1.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- mSphere (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- HHS | NIH | National Institute of Allergy and Infectious Diseases (R01AI114697, NIH2012146)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- cholera toxin B subunit, mucosal immunization, IgA antibodies, Th1/Th2/Th17 responses, cytotoxic T lymphocytes, adjuvant mechanisms, preclinical and clinical trials, vaccine formulation
- MeSH terms
- Adjuvants, Immunologic, Bacterial Toxins, Enterotoxins, Vaccines, Protein Subunits, Escherichia coli Proteins, Mutant Proteins, Administration, Mucosal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

